Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.

Boston Scientific Corporation (BSX)

Healthcare Out of favourS&P 500

Boston Scientific is a global medical technology company that designs and manufactures devices used in minimally invasive medical procedures.

$42.98

Is Boston Scientific Corporation a good stock for a UK beginner?

The honest version: There's no rating here and nothing for sale. In its favour: High gross margins suggest strong demand for their specialised products. Worth weighing: Does not pay a dividend, which may not suit those looking for regular income.

No rating · no target price · nothing for sale here
Price-43.4%
= past earnings-report date
Priced in USD. As a UK investor your £ return also moves with the pound-to-dollar exchange rate, even inside an ISA - a stronger pound can trim your £ gains and a weaker pound can add to them, whatever the share price itself does.
52-week range-55% past year
$42.98
Low $42.20High $109.50
Where today's price sits versus its past year - context, not a signal.

Is this normal for this company?

Each figure against the range this same company has produced recently. Neither end of a range is the good end.

Price to earnings
13.4now
14.338.1

Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.

Net profit margin
16.7%now
12.7%25.8%

Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.

How these ranges are built

Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.

What does Boston Scientific Corporation do?

The company creates tools for doctors to perform surgeries through tiny incisions, focusing on areas like heart health, digestive issues, and pain management. Selling these specialised medical devices to hospitals and clinics worldwide is what generates its earnings. Their momentum hinges on continually innovating and securing regulatory approval for new medical tools in a competitive healthcare market.

On our factor screen it looks strongest on quality and value, and weakest on income.

Quick checks
What's strong
What to watch
  • Momentum screens low
  • Income screens low

Does Boston Scientific Corporation pay a dividend?

No - Boston Scientific Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.

Does Boston Scientific Corporation have more cash or more debt?

It holds about $539.00M in cash against about $12.62B of debt - so it has net debt of about $12.09B. Debt is not automatically a problem - it funds growth - but it has to be serviced and repaid, which matters more when profits wobble.

From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.

What do Boston Scientific Corporation's numbers mean?

P/E
20.72
This shows how much you are paying for every pound of the company's annual profit; a lower number can sometimes suggest a company is cheaper relative to its earnings.
Lower than most of the 60 Healthcare shares we cover
Gross margin
69.2%
This indicates that for every pound of sales, the company keeps nearly 69 pence after paying for the direct costs of making their medical devices.
Higher than most of the 74 Healthcare shares we cover
Beta
0.6
This measures how much the share price tends to swing compared to the wider market; a number below 1 suggests the stock is generally less volatile than the average.
Dividend yield
0.0%
The company does not currently pay out a portion of its profits to shareholders as cash, preferring to reinvest that money back into the business.
Around the middle of the 74 Healthcare shares we cover

How has it performed?

Growth of £1,000, the worst fall, and year by year
If you had put $1,000 into Boston Scientific Corporation
$566-43%

Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

How much has Boston Scientific Corporation actually fallen?

−61%

Over the last 2 years of daily prices, Boston Scientific Corporation fell as much as −61% from a high to a later low. Falls like this are normal when you own a share.

Past falls are not a forecast - it can fall further, or recover.

How has it done year by year?

2022+9%
2023+25%
2024+55%
2025+7%
2026 so far-46%

Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.

A closer look at the numbers

Ownership, earnings history, where the money goes, and the outlook range
Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$74.19B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
20.89M
Day range: The lowest and highest price the shares traded at during the latest day.
$42.80 – $43.55
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$42.20 – $109.50
P/E ratio: Price-to-earnings: the share price divided by yearly profit per share. Lower can mean cheaper; higher often means investors expect fast growth.
20.7
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
0.57

Does the share price tell you if it's cheap or expensive?

One share costs$42.98
Number of shares1.73 billion
So the whole company is worth$74.19bn
A £5 share is not cheaper than a £500 one - it means the company cut itself into more slices. Whether the total looks high or low is what the figures below are for; we don't give a verdict.

Who owns Boston Scientific Corporation?

Big institutions 96%Public & smaller investors 4%

About 96% of Boston Scientific Corporation, or about 96 in every 100 shares, is held by big institutions such as pension and index funds. The rest, roughly 4%, is held by the public and smaller investors.

What this does and doesn't tell you

This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.

How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 0.57
Calm
Wild
Steadier than most

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▲ +4% past week · ▼ -55% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

How much money does Boston Scientific Corporation make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
$0$1.36B$2.72B$4.08B$5.44BQ2 25Q3 25Q4 25Q1 26Q2 26
Gross margin
69.2%
Net margin
17.5%
Return on equity
15.3%

Where does each £100 of Boston Scientific Corporation's sales go?

Making the product or service £31Running costs, tax and interest £52Left as profit £17

A rough split of the latest full-year figures: of every £100 of sales, about £31 covers making the product or service, £52 goes on running costs, tax and interest, and about £17 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.

When does Boston Scientific Corporation report earnings, and how did recent quarters go?

Boston Scientific Corporation is next scheduled to report on about 2026-10-21 - dates can move, and we don't predict results; this just tells you when to look.

‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.

Boston Scientific Corporation: reported versus expected earnings per share, recent quarters
ReportedExpected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number.Actual EPSvs expected
2026-07-29$0.83$0.86Beat +4%
2026-04-22$0.79$0.80Beat +2%
2026-02-04$0.78$0.80Beat +2%
2025-10-22$0.71$0.75Beat +5%
2025-07-23$0.73$0.75Beat +3%
2025-04-23$0.67$0.75Beat +12%

Across the last 6 quarters here, Boston Scientific Corporation came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.

See who else reports over the next two weeks →

Where these figures come from

Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.

What are the scenarios for Boston Scientific Corporation?

An illustrative range for the year ahead — not a prediction or a price target.

◀ lowerhigher ▶todayBull▲ UpsideBase• In-lineBear▼ Downside
Bull
+5% to +10%Stronger than expected demand for new medical device launches.
Base
-2% to +2%Steady performance in line with current market expectations.
Bear
-5% to -10%Supply chain disruptions slowing down product deliveries.

What are the pros, cons and common questions?

The case each way, and the questions people ask
The bull case

Dominance in high-growth minimally invasive surgery markets.

The bear case

Major technological shifts making current product lines obsolete.

What are the pros and cons of Boston Scientific Corporation?

3bull points
6bear points

A balance check, not a score or verdict.

The bull case3
  • High gross margins suggest strong demand for their specialised products.
  • Operates in a sector with steady, long-term demand from an ageing population.
  • Lower beta indicates the stock may be less sensitive to broad market swings.
The catch3
  • Does not pay a dividend, which may not suit those looking for regular income.
  • High reliance on constant innovation to stay ahead of competitors.
  • Subject to strict and often unpredictable government healthcare regulations.
Key risks3
  • Potential for product recalls or legal issues related to medical devices.
  • Changes in government healthcare policy affecting how hospitals are funded.
  • Intense competition from other large medical technology firms.
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

  • A significant, sustained drop in gross margins would suggest pricing power is fading.
  • A major regulatory failure that prevents key products from reaching the market.

Common questions about Boston Scientific Corporation

Does Boston Scientific Corporation pay a dividend?

No - Boston Scientific Corporation does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.

When does Boston Scientific Corporation report earnings next?

Boston Scientific Corporation is next scheduled to report results on about 2026-10-21. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.

More in Healthcare

Veeva Systems Inc.Danaher CorporationGE HealthCare Technologies Inc.Insulet CorporationStryker CorporationMettler-Toledo International Inc.Abbott LaboratoriesIQVIA Holdings Inc.
Confidence: medium · data: USD · flags: none · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Prices as of 11 Sep 2026; other figures as of 11 Aug 2026. Prices may be delayed and numbers can go stale - always double-check before acting.